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ABSTRACT
p53 coordinates the expression of an intricate
network of genes in response to stress signals.
Sequence-specific DNA binding is essential for
p53-mediated tumor suppression. We evaluated
the impact of single-nucleotide polymorphisms
(SNPs) in p53 response elements (p53RE) on DNA
binding and gene expression in response to DNA
damage. Using a bioinformatics approach based
on incorporating p53 binding strength into a
position weight matrix, we selected 32 SNPs in
putative and validated p53REs. The microsphere
assay for protein–DNA binding (MAPD) and allele-
specific expression analysis was employed to
assess the impact of SNPs on p53-DNA binding
and gene expression, respectively. Comparing
activated p53 binding in nuclear extracts from doxo-
rubicin- or ionizing radiation (IR)-treated human
cells, we observed little difference in binding
profiles. Significant p53 binding was observed for
most polymorphic REs and several displayed
binding comparable to the p21 RE. SNP alleles
predicted to lower p53 binding indeed reduced
binding in 25 of the 32 sequences. Chromatin
immunoprecipitation-sequencing in lymphoblastoid
cells confirmed p53 binding to seven polymorphic
p53 REs in response to doxorubicin. In addition,
five polymorphisms were associated with altered
gene expression following doxorubicin treatment.
Our findings demonstrate an effective strategy to
identify and evaluate SNPs that may alter
p53-mediated stress responses.
INTRODUCTION
Although most of the 14.5 million validated human
single-nucleotide polymorphisms (SNPs) listed in the
National Center for Biotechnology Information (NCBI)
dbSNP database (Build 131) are likely nonfunctional,
some can alter cellular responses to a variety of perturb-
ations such as DNA damage, and thereby increase suscep-
tibility to diseases including cancer (1,2). Coding SNPs
alter amino acid sequences and can modify structural
and biological properties of encoded proteins.
Alternatively, regulatory SNPs affect non-coding gene
regions such as introns, enhancers, silencers and pro-
moters. These non-coding sequence variants can modify
transcription factor binding sites (3) or generate novel
binding sites (4–6), which may modulate gene expression
in an allele-speciﬁc manner (7–11). Nevertheless, the
impact of non-coding regulatory SNPs on transcription
factor binding and gene expression has been relatively
unexplored.
The p53 tumor suppressor is a prominent transcription
factor that regulates the expression of an intricate network
of genes in response to DNA damage and other stress
signals (12). This protein coordinates transcriptional
programs primarily by binding to speciﬁc DNA se-
quences, known as p53 response elements (p53REs). The
p53 consensus DNA-binding sequence is composed of
two decameric half-sites, RRRCWWGYYY (where
W=A or T, R=purine and Y=pyrimidine), separated
by a 0–13-bp spacer (13–15). Importantly, sequence-
speciﬁc DNA binding is essential for p53 to exert its
tumor suppressive activity (16–18).
Although p53 plays a signiﬁcant role in protecting cells
against DNA damage (e.g. carcinogenesis), the biological
impact of SNPs in p53 binding sites is largely unknown.
Experimental studies have identiﬁed over 150 functional
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proposed many putative sites where the p53 protein may
bind (19,20). It is likely that many SNPs occur within p53
binding sites, and we have previously identiﬁed several
polymorphisms in putative p53REs that alter p53-DNA
binding and transactivation capacity in an allele-speciﬁc
manner (21,22). These ﬁndings suggest that polymorph-
isms in non-coding gene regulatory regions can modify
transcriptional responses and may represent genetic
risk factors for disease susceptibility. Using a previously
described unique bioinformatics approach (22) that in-
corporates experimentally based p53 binding data, we
conducted a comprehensive search for functional regula-
tory SNPs in experimentally validated (e.g. bona ﬁde)
and putative p53REs that might affect binding. This
in silico strategy provides quantitative predictions of
allele-speciﬁc binding and was used to identify and select
candidate SNPs that were expected to alter p53 binding
and gene expression in response to DNA-damaging
agents.
The microsphere assay for protein–DNA binding
(MAPD) (22,23) was used to evaluate allele-speciﬁc p53
binding to selected sequences. This assay utilizes ﬂuores-
cent microspheres coated with oligonucleotides that
contain speciﬁc binding sequences. Microsphere-
oligonucleotide targets were incubated in nuclear
extracts from cells that contain endogenous levels of
‘activated’ p53, and DNA-bound p53 was detected using
a ﬂow cytometer. An advantage of this assay is its ability
to produce quantitative and biologically relevant protein–
DNA binding measurements.
In this study, we measured the ability of p53 in nuclear
extracts from human lymphoblastoid and U2OS osteosar-
coma cells treated with doxorubicin (DOXO) or ionizing
radiation (IR) to bind six bona ﬁde and 26 putative
p53REs containing SNPs. Most elements displayed signiﬁ-
cant binding above the negative control, and several
putative elements were bound at levels similar to
bona ﬁde p53 binding sites. For most tested sequences,
the alleles that were predicted to lower p53 binding
indeed reduced binding, and the observed effects were in-
dependent of cell type or treatment. Chromatin
immunoprecipitation-sequencing (ChIP-Seq) studies in
cultured human cells conﬁrmed that activated p53
bound to several sequences containing candidate SNPs.
Furthermore, gene expression analysis demonstrated
that several SNPs were associated with reduced gene
transcription. These results illustrate that our bioinfor-
matic approach combined with the MAPD binding
assay and gene expression analysis is an effective
strategy to identify functional SNPs that modify




HapMap (http://hapmap.ncbi.nlm.nih.gov/) CEU human
lymphoblastoid cells (Coriell Cell Repositories, Camden,
NJ, USA) were grown in RPMI 1640 medium
supplemented with 15% heat-inactivated fetal bovine
serum (Invitrogen, Carlsbad, CA, USA) and 1X antibiot-
ics/antimycotics (Gibco, Carlsbad, CA, USA). Human
U2OS osteosarcoma cells (HTB-96, ATCC, Manassas,
VA, USA) were grown in McCoy’s 5A medium supple-
mented with 10% heat-inactivated fetal bovine serum and
1X antibiotics/antimycotics. Cells were incubated at 37  C
with 5% CO2. During experiments, cells were grown in
petri dishes and treated with 0.3 or 0.6mg/ml doxorubicin
(Sigma, St. Louis, MO, USA) for 18h or exposed to 15Gy
ionizing radiation using a Shepherd
137Cesium irradiator
at a dose rate of 0.85krad/min followed by a 5-h incuba-
tion at 37 C.
Western blot
Nuclear proteins were isolated from untreated and treated
cells using the Protein Extract Kit (Active Motif,
Carlsbad, CA, USA). Proteins were quantiﬁed using the
Bradford assay and a HTS 7000
TM Bio Assay Reader
(Perkin Elmer, Waltham, MA USA). Equal amounts
(10mg) of nuclear proteins were electrophoresed on a
NuPAGE 4–12% BisTris gel (Invitrogen) and
transferred to a 0.45-mM nitrocellulose membrane
(Invitrogen). Membranes were probed with primary
anti-p53 mouse monoclonal antibodies (DO-7; BD
Biosciences, San Jose, CA, USA) or anti-b-actin mouse
polyclonal antibodies (C-11; Sigma). Proteins were
detected using goat anti-mouse HRP-conjugated second-
ary antibodies (Bio-Rad, Hercules, CA, USA) and the
enhanced chemiluminescence (ECL) detection system
(Amersham, Piscataway, NJ, USA).
Identiﬁcation of putative functional SNPs in p53REs
By implementing a modiﬁcation of the approach of
Veprintsev and Fersht (24), we created a binding-based
position weight matrix (BPWM) model for quantitatively
predicting p53-DNA binding (22) and incorporated this
into our previous SNP identiﬁcation strategy (25,26).
Brieﬂy, a delta-binding matrix was generated by subtract-
ing experimentally measured p53 binding values for
60 variants of the ConA sequence (a perfect match to
the p53 consensus binding motif) from binding to the un-
modiﬁed sequence. Equations (2), (A.1) and (A.2) from
Veprintsev and Fersht (24) were applied to the
delta-binding matrix to generate the BPWM model.
In our current study, the BPWM model was used to
identify and score SNPs within the human genome that
alter p53-DNA binding. Brieﬂy, utilizing the delta-binding
matrix, each allele was scored independently, and the
difference between the two scores was used to estimate
the SNP impact on p53-DNA binding. We identiﬁed
SNPs in putative p53REs by searching the NCBI dbSNP
(Build 129) database for polymorphisms in sequences that
matched the p53-DNA binding motif. We identiﬁed SNPs
in validated p53REs by mapping NCBI dbSNP database
entries into a list of 150 experimentally discovered
p53REs.
Several SNPs in putative p53REs (rs2838769,
rs3806624, rs1658728, rs3761624 and rs1465952) have pre-
viously been tested in our group using MAPD (22) and
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included in this study to evaluate their effects in different
cell types and under different experimental conditions.
Microsphere assay for protein–DNA binding
Allele-speciﬁc p53 binding was evaluated using the MAPD
assay, as previously described (22,23). Brieﬂy,
MicroPlex
TM-xTAG microspheres (Luminex, Austin,
TX, USA) were hybridized to double-stranded oligo-
nucleotides (Invitrogen) containing unique p53 binding
sites and a biotin moiety on the 50-end of the reverse
strand. Hybridization reactions were carried out in a poly-
merase chain reaction (PCR) thermocycler. Microsphere-
oligonucleotide targets were pooled and washed in a
MultiScreenHTS-BV ﬁlter plate (Millipore, Bedford,
MA, USA) with Assay Buffer A (Cytokine Reagent Kit,
Bio-Rad).
Sequence-speciﬁc p53 binding was examined 1h after
incubating targets in reaction mixtures that contained
non-competing double-stranded oligonucleotides
(TransAm p53 kit, Active Motif) and nuclear extracts
from doxorubicin- or IR-exposed human cells. Negative
and positive control sequences were examined in each
reaction. Nuclear extracts from untreated cells served as
an additional negative control. Microspheres were washed
and incubated for 30min with primary anti-p53 monoclo-
nal antibodies (DO-7) followed by a 30-min incubation
with phycoerythrin-conjugated secondary antibodies. p53
DNA binding was measured by ﬂow cytometric analysis
using a Bio-Plex 200 System (Bio-Rad).
p53 ChIP-Seq
Chromatin immunoprecipitation methods and buffers
were from the Agilent Mammalian ChIP-on Chip
protocol (Agilent, Version 10.0, May 2008). Brieﬂy, 10
8
DOXO or untreated lymphoblastoid cells (GM06993 and
GM11992) were formaldehyde crosslinked and lysed to
obtain nuclear cell pellets. Pellets were resuspended, chro-
matin was sonicated into 200–500-bp fragments using
a Misonix 3000 sonicator (30 pulses—30 s on followed
by 20 s off—at 100% power) (Farmingdale, NY, USA),
and the supernatant was collected after centrifugation.
Using either mouse monoclonal antibody DO-7
(BD Biosciences) or a non-speciﬁc rabbit IgG
(Invitrogen) conjugated to secondary Dynal magnetic
beads (Invitrogen), 5 10
7 isolated nuclei were immuno-
precipitated overnight (4 C), beads were washed, and
protein–DNA crossslinks reversed overnight (65 C).
After digestion of RNA and cellular protein, DNA
was isolated using phenol chloroform extraction and a
phase lock gel (Sigma), and subsequently puriﬁed using
Qiaquick PCR Puriﬁcation Kit (Qiagen, Germantown,
MD, USA) according to the manufacturer’s instructions.
Puriﬁed ChIP DNA was dried, resuspended in
double-distilled H2O, and quantiﬁed using PicoGreen
(Invitrogen). p53 ChIP DNA from the two cell lines
were combined for each condition (DOXO-treated,
untreated, and IgG ChIP).
The National Center for Genome Resources (Santa Fe,
NM, USA) sequenced the immunoprecipitated samples on
the Illumina Genome Analyzer II. Brieﬂy, sequencing
adapters were ligated to immunoprecipitated DNA and
size-selected by gel electrophoresis (250±25bp).
Fragments were PCR-ampliﬁed (18 cycles) and sequenced.
Short reads were mapped to the human reference genome
(Build 36.3) using Burrows-Wheeler Alignment (BWA)
Tool (27). By default, BWA ﬁnds an alignment
(ungapped and gapped) with maximum edit-distance 2
to the 36bp query sequence, except for disallowing gaps
close to the end of the query.
Uniquely mapped short reads from p53-immuno-
precipitated DNA were used to identify regions of the
genome with signiﬁcant enrichment in p53-associated
DNA sequences, hereafter referred to as ‘peaks’ owing
to their appearance in genome-wide density plots. The
peak detection was performed by QuEST 2.4 software
(28) using a ‘transcription factor binding site’ setting
(bandwidth of 30bp, region size of 300bp) and default
stringency (corresponding to 50-fold ChIP to input enrich-
ment for seeding the regions, and 3-fold ChIP enrichment
for extending the regions).
Gene expression analysis
To evaluate the allele-speciﬁc effects of SNPs on gene
expression, 23 HapMap CEU human lymphoblastoid
cell lines were cultured in triplicate and treated with
0.6mg/ml doxorubicin for 18h. RNA was isolated with
RNeasy columns (Qiagen) and cDNA was generated
using the First-Strand Synthesis system (Invitrogen). For
each biological replicate, target genes were ampliﬁed in
triplicate using SYBR primers designed to span exon junc-
tions for each target gene (see Supplementary Table S2)
and Power SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA, USA). Fluorescence inten-
sity was measured using a PRISM HTS 7900 System
(Applied Biosystems) and the initial ﬂuorescence
(Ro value) of each ampliﬁed sample was calculated using
the method described by Peirson and colleagues (29).
Target values were normalized to GAPDH mRNA
measurements.
RESULTS
In silico selection of candidate SNPs for
functional evaluation
Using a novel bioinformatics approach (Figure 1), we
identiﬁed 6538 SNPs in the NCBI dbSNP (Build 129)
database that were located in putative p53 binding sites
and were predicted to alter p53–DNA interactions. We
also identiﬁed 33 polymorphic sequences in experimentally
validated p53 binding sites. After applying additional pri-
oritization criteria, 32 SNPs were selected for functional
evaluation. Six of these variants were located within 5kb
of the transcription start site of bona ﬁde p53-responsive
genes. SNP selection was based on the requirement that:
(i) each site contained all four conserved core C and G
nucleotides in at least one allele; (ii) each site contained at
least three of the four consensus ‘W’ (A or T) nucleotides
in at least one allele; (iii) each site contained a spacer
 1-bp separating the two half-sites; (iv) the BPWM
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(an indicator of a moderate-to-high p53 binding
sequence); and (v) the polymorphism was predicted to
alter p53-DNA binding. The candidate SNPs and
associated REs are described in Table 1.
MAPD evaluation of allele-speciﬁc p53 binding to
polymorphic sequences
To overcome the limitations of traditional methods used
to quantify protein–DNA binding, we have developed a
microsphere-based DNA binding assay to measure
p53-RE interactions (22). As seen in Figure 2, allele-
speciﬁc binding was observed after incubating bead-
oligonucleotide targets in nuclear extracts from human
lymphoblastoid cells that were either untreated or
treated with doxorubicin (DOXO). p53 binding levels in
untreated samples were <2% of levels observed in treated
samples. In addition, allele-speciﬁc differences in binding
were not observed in untreated cells (data not shown).
In contrast, p53 in extracts from DOXO-treated
cells bound to the predicted strong allele of 29 REs at
levels that were above the negative control sequence
(WRNC). Moreover, the tumor suppressor bound
several validated REs at levels that were comparable to
or greater than those observed for the positive control
(a bona ﬁde p53RE  2kb upstream of the p21 gene tran-
scription start site) (see EDN2, RRM2B and TRIM22).
Some putative REs bound p53 at levels similar to
validated p53 binding sites (see ADARB1, EOMES,
PSMA6, TNFSF14, TPP2 and UBA3). Compared to
the predicted strong alleles, binding to the predicted
weak alleles was signiﬁcantly reduced for  80% of
the elements (P<0.05, t-test). For 10 of these variants,
the SNP diminished p53 binding by  50%.
Furthermore, the polymorphic sequences associated with
FUCA1, PMAIP1, RRM1 and TLR8 nearly abolished the
ability of p53 to recognize the binding sites. It should also
be noted that our bioinformatic calculations were gener-
ally accurate for predicting p53 binding to REs with high
scores (>100) and for estimating the SNP effect on
binding.
ChIP-Seq conﬁrms p53 binding to sequences
containing SNPs
To date, only one p53 ChIP-seq study has been published,
which was carried out in a colon cancer cell line treated
with 5-ﬂuorouracil (5-FU) (20). We applied ChIP-Seq
to HapMap lymphoblastoid cells to determine whether
DOXO induces p53 to bind to our selected sequences.
Detailed information on the ChIP-Seq experiment
and data analysis will be reported separately. Here,
we only show limited data corresponding to the gen-
omic regions selected for this study. After mapping
sequenced p53-ChIP fragments to the human reference
genome (Build 36.3), we observed that p53-bound se-
quences were enriched for seven of the 32 tested
binding sites (Figure 3). It should be noted that four
of these p53-bound sites correspond to sequences
that had not been previously conﬁrmed as p53
binding sites. Additional sequence analysis revealed
that the candidate SNPs occurred within the p53-
bound sites. These ﬁndings combined with our
MAPD binding data suggest that a number of the
bioinformatics-selected sequences are indeed bound by
p53 in cultured human cells treated with DOXO and
Figure 1. In silico selection of candidate p53RE SNPs. Computational analysis was used to identify human SNPs in experimentally validated and
putative p53REs that are predicted to alter p53 binding.
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binding in vivo.
Doxorubicin induces allele-speciﬁc transcription in
human cells
To determine if the selected SNPs alter gene transcription,
we performed RT-qPCR on RNA isolated from untreated
and DOXO-treated HapMap CEU cell lines that
were homozygous for either the predicted strong or
weak allele. Relative to untreated cells, nine of
11 analyzed genes were induced in response to DOXO
treatment (Figure 4). Allele-speciﬁc differences in gene ex-
pression were observed for ADARB1, PSMA6, TNFSF14,
TRIM22 and UBA3 where the weak allele displayed
lower levels of expression (P<0.05, t-test). Expression
levels for TPP2 and SFRS12 were not induced in
response to DOXO, which suggests that they are not
regulated by the tumor suppressor. The other tested
genes had modest allelic differences in expression. These
ﬁndings suggest that SNPs in p53 binding sites can
alter gene expression in response to DNA-damaging
agents.
Allele-speciﬁc p53 binding is independent of cell
type-speciﬁc effects
p53 is a versatile transcription factor with distinct
roles that are inﬂuenced by cell type (30) and treatment
(31,32). To evaluate cell-type speciﬁc contributions to
p53-DNA binding, p53 binding to a subset of REs in nu-
clear extracts from DOXO-treated U2OS osteosarcoma
cells was compared to results observed in lymphoblastoid
cells. REs that displayed either weak p53 binding
(<10% relative to the positive control) or no allele-speciﬁc
binding differences in DOXO-treated lymphoblastoid
nuclear extracts were excluded from further analysis. As
seen in Figure 5A, DOXO-activated p53 from U2OS
cells bound each sequence at levels that were comparable
to DOXO-activated p53 from lymphoblastoid cells
(see Figure 2). A linear regression analysis of binding in
lymphoblastoid versus U2OS extracts produced r
2 values
of 0.92 and 0.94 for strong and weak alleles, respectively
(data not shown). Linear regression analysis comparing
SNP-induced binding changes in both cell lines
demonstrated that the SNP effect on binding were also
similar (r
2=0.87, Figure 5B).
Table 1. Candidate p53RE SNPs








rs3809024 CASP1 GT*CATGCATATGCATGTCT G (123.0) A (119.0) 4.0 Apoptosis
rs62216320 COL18A1 TGACA*GTGTGAGCATGTAT T (126.1) C (120.0) 6.1 Extracellular matrix
rs11572355 EDN2 CTGCAAGCCC*GGCATGCCC G (129.4) A (128.0) 1.4 Vasoconstriction
rs62122432 GDF15 CATCTTG*CCAGACTTGTCT C (123.0) T (117.3) 5.7 Cell signaling
rs28999675 RRM2B TGACATGCC*AGGCATGTCT C (134.7) G (132.4) 2.3 Nucleic acid metabolism
rs35926783 TRIM22 TGACATGTCT*GGCATGTAG G (137.3) A (135.0) 2.3 Immune response
Putative response elements
rs2838769 ADARB1 GGACAAGTTGAAACTT*CAC G (113.1) A (100.7) 12.4 Nucleic acid metabolism
rs2033654 ADCY3 GGACCT*GCCTAACATGTCA G (108.3) T (93.9) 14.4 Intracellular signaling
rs1658728 ARHGEF7 AAACATGTCA*CACTTGCTT G (124.2) T (121.8) 2.4 Apoptosis
rs3806624 EOMES CAACT*GCCCCAGTTTCCCC T (117.4) C (105.9) 11.5 Development
rs12105811 CFLAR GATCCTGCTTGGTC*TGTCC A (109.5) G (105.2) 4.3 Apoptosis
rs10917431 FUCA1 GGGC*TGTCCACTCAGGTCT A (123.8) C (112.9) 10.9 Carbohydrate metabolism
rs9282701 HMOX1 GAGCCAGCACGAACGAGCC* C (103.6) T (103.0) 0.6 Oxidative stress response
rs11855354 IDH3A TTTCAG*TTGTGGCCAGGCA G (104.4) A (90.0) 14.4 Carbohydrate metabolism
rs3755276 IL18R1 ATGCATGTGTTCGC*TGTGT A (124.0) G (119.7) 4.3 Immune response
rs2410545 NAT1 CCTC*TGTCAGGGCATGGGA A (122.8) G (111.3) 11.5 Xenobiotic metabolism
rs1941404 NNMT TAACA*GCACACACATGGGC T (123.0) C (118.7) 4.3 Nucleic acid metabolism
rs12409754 PGD GGGCA*GGTGTTGCATGCCT T (118.2) C (112.1) 6.1 Carbohydrate metabolism
rs7240884 PMAIP1 CAACAT*TTTGATCTTGTAG G (112.1) A (97.7) 14.4 Apoptosis
rs1048990 PSMA6 GTGCTT*TACCAACATGTCC G (112.4) C (97.8) 14.6 Protein metabolism
rs1003619 RANGAP1 CC*CAAGCCCCACCAAGCCC G (112.1) C (97.7) 14.4 Cell signaling
rs6017447 RPN2 CACCATGT*CgGCTCATGTTT C (119.6) G (115.8) 3.8 Protein metabolism
rs1465952 RRM1 GGG*ATGTGCATTCAAGTTT C (120.6) T (108.1) 12.5 Nucleic acid metabolism
rs27078 SFRS12 TGGCATGTCTTCA*ATGTAG C (125.6) G (111.0) 14.6 Nucleic acid metabolism
rs505802 SLC22A12 CCAC*TGCCCtGTACATGCTT A (136.2) G (132.0) 4.2 Ion transport
rs1678199 SP100 TGGCA*GTATTGGCATGACC A (125.4) C (124.8) 0.6 Immune response
rs3761624 TLR8 AGGCAAGATGAAACAT*TCA G (111.9) A (101.1) 10.8 Immune response
rs1077667 TNFSF14 GTGC*TGTACCCACATGTCC A (123.5) G (112.0) 11.5 Immune response
rs3783231 TPP2 CCACATG*AAAGGCATGTAT T (126.4) C (121.8) 4.6 Protein metabolism
rs10455025 TSLP GAACATGGCA*GACATGAAA A (123.8) C (122.6) 1.2 Extracellular matrix
rs3853154 UBA3 AGACATGTATCATCATGC*C C (118.1) A (114.6) 3.5 Protein metabolism
rs11248877 UNKL GGGC*TGGTGGCACATGCCT A (119.2) G (115.0) 4.2 Nucleic acid metabolism
Thirty-two candidate p53RE SNPs were selected for functional evaluation. Six SNPs are associated with bona ﬁde p53 regulated genes. Genes located
near the SNPs are listed. Sequences and SNP position (asterisk) within the element are shown. Sequences are aligned to the p53 consensus binding
sequence (lower case letters represent 1-bp spacers). The predicted strong and weak allele is shown for each site along with the corresponding
predicted binding value (BPWM). BPWM indicates the negative effect each SNP is predicted to have on p53 binding.
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p53-RE binding, we compared binding in nuclear
extracts from IR-exposed lymphoblastoid and U2OS
cells. As seen in Supplementary Figure S1A
(lymphoblastoid cells) and B (U2OS cells), IR-activated
p53 binding levels were similar in both extracts
(r
2=0.95 and 0.97 for strong and weak alleles, respective-
ly; data not shown). The SNP effects on p53 binding also
were similar in both cell types (r
2=0.90, Supplementary
Figure S1C). These results demonstrate that the effects of
the polymorphisms on p53-DNA binding are independent
of cell-type speciﬁc differences between the two cell lines.
Allele-speciﬁc p53 binding is independent of
treatment-speciﬁc effects
To determine if treatment-speciﬁc effects alter p53–DNA
interactions, we compared binding in nuclear extracts
from IR-exposed lymphoblastoid cells to results
observed in extracts from DOXO-treated cells. In
Figure 6A, the pattern of IR-induced p53 binding to the
predicted strong alleles was similar to the pattern induced
by DOXO (see Figure 2). As seen with DOXO, reduced
binding to the weak alleles was also observed in extracts
from IR-exposed cells (P<0.05 for all allele pairs, t-test).
Moreover, a strong correlation was shown for SNP-
induced changes on p53 binding between DOXO and IR
treatment (r
2=0.86, Figure 6B).
To further determine if treatment-speciﬁc effects modify
p53-RE binding, we compared p53 binding in nuclear
extracts from DOXO- and IR-exposed U2OS cells. As
seen in Supplementary Figure S2, the SNP effects on
p53 binding were also similar in response to both treat-
ments (r
2=0.73). These ﬁndings indicate that the impact
of sequence variation on p53-RE binding is mostly un-
affected by treatment-speciﬁc effects induced by these
DNA-damaging agents.
Figure 2. Evaluation of sequence-speciﬁc p53 DNA-binding in human cells. The MAPD assay was used to assess p53 binding to predicted strong
(black bars) and weak (gray bars) alleles in nuclear extracts from DOXO-treated (0.6mg/ml for 18h) human lymphoblastoid cells that were sup-
plemented with 150pmol of non-competing oligonucleotides. p53 binding is displayed relative to a bona ﬁde p53RE upstream of the p21 gene (set to
100%). A negative control sequence (WRNC) was included in each experiment. Polymorphic alleles that displayed signiﬁcant differences in p53
binding (P<0.05, t-test) are indicated by (asterisk). SNPs previously tested under these experimental conditions using the MAPD assay (21,22) are
indicated by (y). Error bars represent the standard deviation of three independent experiments carried out in triplicate.
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effects on p53 binding
Although base changes involving the highly conserved
C and G nucleotides at positions 4 and 7 in each
p53RE half-site signiﬁcantly reduce p53 binding, most
functional REs deviate from the consensus binding
sequence (22,33,34). Variations in p53RE sequences and
p53 protein levels contribute greatly to gene transactiva-
tion mediated by the tumor suppressor (23,33,35).
Understanding this relationship is important for
determining how p53 inﬂuences cellular responses to
stress. To further examine the effects of polymorphic se-
quences on p53-DNA binding, we evaluated ADARB1
and RRM2B RE allele pairs in the presence of increasing
amounts (0–4mg) of nuclear extracts from DOXO-treated
lymphoblastoid cells. The RE associated with ADARB1
contains a G-to-A change at position 7 in the second
half-site, while the RE associated with RRM2B has a
C-to-G change adjacent to position 4 and 7. As seen in
Figure 7A, modiﬁcation of the preferred G in the
ADARB1 RE dramatically reduced p53 binding. For
example, at 4mg of nuclear extracts, the predicted weak
allele reduced p53 binding by 3.5-fold relative to the pre-
dicted strong allele.
The base change in the RRM2B RE had modest
effects on p53 binding compared to the strong allele
(see Figure 7B). At 4mg of nuclear extracts, p53 binding
was 0.44 and 0.39 for the predicted strong and weak allele,
Figure 3. Evaluation of p53-DNA binding in human cells using ChIP-Seq. Human lymphoblastoid cells were treated with 0.3mg/ml DOXO for 18h
and crosslinked with formaldehyde. Genomic DNA was sonicated, immunoprecipitated with p53 antibodies, sequenced and mapped to the human
reference genome. Green peaks in (A–H) represent sequenced reads from DOXO-induced p53–DNA binding in the regulatory region of nearby
genes. QuEST software was used to normalize p53 ChIP-Seq reads to control samples (IgG ChIP-Seq reads). As a positive control, panel A displays
p53 ChIP-Seq peaks that contain bona ﬁde p53REs which are located within the CDKN1A (p21) promoter region (see also Supplementary Figure
S3). (B–F) illustrates that the SNPs are located within the p53 binding sites (denoted by arrows). Note: (A–D) display strong p53-DNA binding, and
show relatively weak binding.
184 Nucleic Acids Research, 2011,Vol. 39,No. 1respectively. These results suggest that polymorphisms
that alter the highly favored bases at position 4 and 7 in
p53RE half-sites can have signiﬁcant effects on
p53-mediated responses to DNA damage, whereas other
changes may be better tolerated.
DISCUSSION
Non-coding regulatory SNPs in transcription factor
binding sites can have signiﬁcant biological consequences
(1). We carried out a comprehensive genome-wide bio-
informatics search using a unique prediction model
(BPWM), to identify human SNPs in validated and
putative p53-targeted sequences that were predicted to
alter p53 binding following exposure to DNA-damaging
agents. The selected SNPs were evaluated using the
MAPD binding assay and gene expression analysis to de-
termine the functional impact of each variant. We
employed ChIP-Seq analysis to conﬁrm p53 sequence-
speciﬁc binding in cultured human cells in response to
doxorubicin, a DNA-damaging agent. To our knowledge,
this represents the ﬁrst study that examines properties of
SNPs that co-locate with ChIP-seq peaks. The
allele-speciﬁc differences observed for p53 target genes
following exposure to doxorubicin support the hypothesis
that genetic variation in non-coding regulatory sequences
may impact risk in environmentally induced diseases such
as cancer (1). Our ﬁndings also demonstrate that this bio-
informatics strategy can identify SNPs in gene regulatory
regions that alter p53–DNA binding and gene expression.
In addition, we believe regulatory SNPs that affect other
transcription factors or DNA binding proteins can be
identiﬁed and evaluated using a similar approach.
Many of the sequences we identiﬁed have not been ex-
perimentally validated as p53REs. Our results, using
MAPD, gene expression and ChIP-seq methods, demon-
strate that p53 binds putative polymorphic REs near
ADARB1, HMOX1, PSMA6 and TNFSF14 in cultured
human cells, which suggests that these genes are novel,
previously unidentiﬁed components of the p53 transcrip-
tional network. Several polymorphic sequences that were
tested are associated with genes that have tumor suppres-
sive activity, play roles in cell cycle regulation, or function
in other cellular processes associated with p53-mediated
signaling pathways. ADARB1 is a member of the adeno-
sine deaminase family, which plays important roles during
developmental processes. This RNA-editing enzyme is
suggested to have negative effects on the development
Figure 4. Evaluation of allele-speciﬁc gene expression in DOXO-treated human cells. Allele-speciﬁc expression of genes adjacent to polymorphic REs
was measured in HapMap human CEU lymphoblastoid cell lines after exposure to 0.6mg/ml DOXO for 18h. RT-qPCR analysis was carried out on
cell lines that were homozygous for the predicted strong or weak allele. Expression was normalized to GAPDH expression levels. Values represent
induction levels relative to untreated cells. The number of homozygous cell lines examined for each allele is denoted by ‘n’. Homozygous weak alleles
that displayed signiﬁcant differences in expression (P<0.05, t-test) are indicated by asterisk. Error bars represent the standard deviation of triplicate
RT–qPCR reactions carried out on each of three biological replicates for all cell lines.
Nucleic AcidsResearch, 2011, Vol.39,No. 1 185Figure 6. Evaluation of treatment-speciﬁc effects on p53 binding to polymorphic alleles. (A) The MAPD assay was used to assess p53 binding to
predicted strong (black bars) and weak (gray bars) RE alleles in nuclear extracts from IR-treated (15Gy followed by a 5-h recovery) human
lymphoblastoid cells. All other experimental conditions and data analysis was performed as described in Figure 2. Each allele pair displayed
signiﬁcant differences in p53 binding (P<0.05, t-test). Error bars represent the standard deviation of three independent experiments carried out
in triplicate. (B) Regression analysis was used to compare the effect of each SNP on p53 binding in nuclear extracts from human lymphoblastoid cells
treated with DOXO versus IR.
Figure 5. Evaluation of cell type-speciﬁc effects on p53 binding to polymorphic alleles. (A) The MAPD assay was used to assess p53 binding
to predicted strong (black bars) and weak (gray bars) alleles in nuclear extracts from DOXO-treated (0.6mg/ml for 18h) human U2OS cells. All
other experimental conditions and data analysis was performed as described in Figure 2. Each allele pair displayed signiﬁcant differences in
binding (P<0.05, t-test). Error bars represent the standard deviation of three independent experiments carried out in triplicate. (B) Regression
analysis was used to compare the effect of each SNP on p53 binding in nuclear extracts from DOXO-treated human lymphoblastoid versus U2OS
cells.
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of the peptidase T1A family and a subunit of the prote-
asome 20S catalytic core. The core is involved in cell-cycle
regulation and differentiation and is expressed in malig-
nant cells (37,38). PSMA6 is involved in the development
of hepatocellular carcinoma (39) and breast cancer (38).
TNFSF14 is a ligand for a member of the tumor necrosis
factor receptor superfamily, which stimulates the prolifer-
ation of T cells and triggers apoptosis of various tumor
cells (40,41). TRIM22 is an interferon-inducible protein
and is a p53 target gene. TRIM22 has antiproliferative
effects in leukemic cells (42) and is suggested to play
lineage-speciﬁc roles during hematopoietic differentiation
(43). UBA3 is the catalytic subunit of the NEDD8-activing
enzyme. NEDD8 is involved in the regulation of cell
division and cell signaling. UBA3 is essential for the
antiproliferative activity of an antiestrogen drug that is
targeted against estrogen receptor alpha positive breast
cancer cells (44).
In this work, we have used de novo approaches to
identify and test polymorphic REs that alter p53–DNA
binding. These SNPs may also alter cellular stress re-
sponses and increase disease susceptibility in vivo. Our
results further illustrate the signiﬁcance of the conserved
C and G in the p53-DNA binding motif. We demonstrate
that this observation is apparent in both moderate
(ADARB1 and TLR8) and low (PMAIP1 and RRM1)
afﬁnity p53 binding sites, which suggests that sequence
variations involving these nucleotides will have the most
signiﬁcant biological consequences. In contrast, SNPs that
alter nucleotides outside of the conserved C and G may
have little impact and produce no obvious phenotypic
effects.
In this study, we identiﬁed SNPs that alter p53-RE
binding and impact gene expression; however, the func-
tional, evolutionary and risk implications of these effects
are not always obvious. For example, we observe occa-
sionally that the less common, minor allele is the predicted
strong allele, displaying both stronger binding (e.g.
rs1077667, TNFSF14; rs1048990, PSMA6) and stronger
transactivation while the common (i.e. ancestral allele,
shared with other primates) allele displays weaker
binding. This suggests that the recently created, stronger
allele may have some selective advantage in human
lineages that have it. However, selective advantage
(positive selection) or disadvantage (purifying selection)
is related to reproductive success, while cancer risk
is related to somatic processes that impact a post-
reproductive disease outcome. Although it is unclear
whether the creation of these speciﬁc strong-binding
alleles in the human population affects physiology,
survival or risk, transcriptional pathways can evolve in
this way (45–47). Menendez et al. (6) have suggested
that an SNP may create novel binding sites and connect
transcriptional pathways. The impact of RE polymorph-
isms is further complicated by the possibility that speciﬁc
p53RE ‘WW’ dinucleotide combinations can inﬂuence
whether p53 activates or represses gene expression (48).
Thus, an SNP that occurs in a RE from which p53
represses transcription could decrease p53 binding and
thereby increase gene expression. This scenario may
explain the increased expression of PMAIP1 in cell lines
homozygous for the weak allele. Evaluating SNPs in
p53REs that are predicted to repress transactivation
would be of great interest.
The p53 protein plays key roles during the cellular stress
response (12), which can be inﬂuenced by cell type (30). A
number of reports have demonstrated that different stress-
inducing agents trigger a variety of p53 post-translational
modiﬁcations (49,50) and differential transactivation of
target genes (51,52). Two recent publications disagree
with regard to whether different agents produce different
p53 occupancy proﬁles at native binding sites in cells.
Shaked et al. (53), using ChIP-on-chip, observed that
global patterns of p53 occupancy differed very little
among gamma irradiated, DOXO, 5-FU or UV treated
HCT116 and U2OS cell lines. Millau et al. (54) using a
more sensitive technique, observed unique p53 occupancy
patterns over time at different p21 response elements fol-
lowing treatment with 5-FU, Nutlin-3, UV and gamma
Figure 7. Evaluation of SNP sequence position on p53–DNA binding.
The MAPD assay was used to assess p53 binding to predicted strong
(closed circles) and weak (open circles) RE alleles that are associated
with (A) ADARB1 and (B) RRM2B. Beads bearing the speciﬁc REs
were incubated with increasing amounts of nuclear extracts (0–4mg)
from DOXO-treated (0.6mg/ml for 18h) human lymphoblastoid cells
in the presence of 150pmol of non-competing oligonucleotides. A
negative control sequence (WRNC, asterisks) was included.
Polymorphic sequences are aligned to the p53 consensus RE
sequence. The asterisk above the sequences represents the position of
the polymorphic nucleotide. Binding values represent the mean of three
independent experiments carried out in triplicate.
Nucleic AcidsResearch, 2011, Vol.39,No. 1 187radiation. The MAPD assay evaluates the p53 binding
step and provides high resolution and discrimination of
small binding differences. The present ﬁndings using
DOXO and IR in lymphoblastoid and U2OS osteo-
sarcoma cells clearly demonstrate that very similar p53
binding patterns are produced from p53 activated under
all experimental conditions tested. Thus, it is likely that
other features in the transcription process, such as the
chromatin environment or stress-speciﬁc cofactors, may
contribute to cell type- and treatment-speciﬁc p53
binding and subsequent transactivation in cells (51,52).
In addition, we demonstrate for the ﬁrst time that individ-
ual SNPs produced similar effects on p53–DNA binding
regardless of the cell type or stimulus used for activation.
The present study suggests that sequence variation
in p53 binding sites can impact binding and potentially
modify p53-mediated responses to DNA-damaging
agents. The MAPD binding assay is a useful way to
estimate the functional impact of nucleotide changes in
target binding sites and could be applied to other tran-
scription factors. Developing quantitative binding data
for many regulatory elements may allow us to elucidate
the impact of polymorphic variation on transcriptional
networks.
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